HGHeval Atas Guvenilir

Heval Atas Guvenilir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Heval Atas Guvenilir has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • KG-Orchestra: An open-source multi-agent framework for evidence-based biomedical knowledge graphs enrichment

    by Ahmed Hossameldin Mohamed, Karim S Shalaby, Abish Kaladharan, Sutrishna Sen, Heval Atas Güvenilir, Alpha Tom Kodamullil

  • Open Access

    Converging pathomechanisms link SARS-CoV-2 infection with major neurodegenerative diseases

    by Feng Q. HeFeng, Andrea Martí-Sarrias, Heval Atas Guvenilir, Renata Baptista Vieira de Sá, Adithya Sridhar, Undine Haferkamp, Fatima El Kach-Marso, Sarah Bauermeister, Anett Hudák, Aristeidis Roubanis, et al.

    Neurological complications are among typical clinical manifestations, both during the acute phase of SARS-CoV-2 infection and long-term post-acute COVID-19 sequelae, i.e., Long COVID. A growing body of evidence connects SARS-CoV-2 infection to systemic inflammation, peripheral immune dysregulation, functional alteration of the blood–brain barrier (BBB), neuroinflammatory processes, mitochondrial dysfunction and pathological protein aggregation, all of which are central to the pathogenesis of major neurodegenerative diseases. In this review, we discuss the converging shared underlying molecular mechanisms that link the ‘acute’ SARS-CoV-2 infection that often only lasts for days and ‘chronic’ neurodegenerative diseases that often take decades to develop. We further review human induced pluripotent stem cells (iPSCs)-derived brain organoid and BBB models for Parkinson’s disease (PD) and Alzheimer’s disease (AD) as well as artificial intelligence (AI)-facilitated knowledge graph methods that are used to hypothesize and validate the potential mechanistic links. We propose that besides the established links between viral infections and neurodegenerative or neuroinflammatory conditions, such as Epstein-Barr virus (EBV) in multiple sclerosis or herpes zoster in AD, SARS-CoV-2 infection might be another important factor driving the future burden of the most common neurodegenerative diseases. Graphical Abstract Schematic illustrating the potential link between the progression from SARS-CoV-2 infection and immune dysregulation to the development of Long COVID and eventually the subsequent onset of major neurodegenerative diseases (e.g., Parkinson's disease and Alzheimer's disease).

  • Open Access

    Converging Pathomechanisms Link SARS-CoV-2 Infection With Major Neurodegenerative Diseases

    by Feng Q. HeFeng, Andrea Martí-Sarrias, Heval Atas Guvenilir, Renata Vieira de Sá, Adithya Sridhar, Undine Haferkamp, Fatima El Kach-Marso, Sarah Bauermeister, Anett Hudák, Aristeidis Roubanis, et al.

    Background: Neurological complications are among typical clinical manifestations, both during the acute phase of SARS-CoV-2 infection and long-term post-acute COVID-19 sequelae, i.e., Long COVID. A growing body of evidence connects SARS-CoV-2 infection to systemic inflammation, peripheral immune dysregulation, blood-brain barrier (BBB) dysfunction, neuroinflammatory processes, mitochondrial dysfunction and pathological protein aggregation, all of which are central to the pathogenesis of major neurodegenerative diseases. Main Body: In this review, we discuss the converging shared underlying molecular mechanisms that link the ‘acute’ SARS-CoV-2 infection that often only lasts for days and ‘chronic’ neurodegenerative diseases that often take decades to develop. We further review human induced pluripotent stem cells (iPSCs)-derived brain organoid and BBB models for Parkinson’s disease (PD) and Alzheimer’s disease (AD) as well as artificial intelligence (AI)-facilitated knowledge graph methods that are used to hypothesize, discover and validate the potential mechanistic links. Conclusions: We suggest that besides the established links between viral infections and neurodegenerative or neuroinflammatory conditions, such as Epstein-Barr virus (EBV) in multiple sclerosis or herpes zoster in AD, SARS-CoV-2 infection is another important factor defining the future burden of the most common neurodegenerative diseases.

  • Open Access

    ECLIPSE: Exploration of Complex Ligand-Protein Interactions through Learning from Systems-level Heterogeneous Biomedical Knowledge Graphs

    by Heval Atas Guvenilir, Tunca Doğan

    Discovering new, efficacious molecules remains slow and costly; rigorous data science-driven systems-level approaches are therefore essential to prioritise hypotheses and de-risk drug development. In this study, we present ECLIPSE, a systems-level framework for compound/ligand–protein interaction (CPI) representation and prediction, combining heterogeneous knowledge graphs (KGs), which encode large-scale entity–relation structure, with graph neural networks that exploit relational inductive biases to perform inference on graph-structured data. ECLIPSE uses our comprehensive biomedical KG-based platform, CROssBAR, incorporating genes/proteins, drugs, compounds, pathways, diseases, and phenotypes, along with their multi-layered relationships. Each entity is assigned input features derived from language or graph representation learning models and projected via type-specific neural network layers. To process these featurized biomedical KGs for bioactivity prediction, we employed the heterogeneous graph transformer (HGT) architecture. In contrast to the majority of GNN algorithms, which are restricted to homogenous graphs, HGT can handle graph heterogeneity and maintain node-and edge-type dependent representations through its attention mechanism. ECLIPSE achieves strong performance on challenging, protein-family– specific CPI benchmarks compared with baseline and state-of-the-art methods; ablations confirm performance gains from modelling graph heterogeneity and all feature sources. Use-case analyses on a druggable kinase (PIM1) and a historically undruggable receptor (HER3) illustrate generalizability across target classes and activity ranges. By leveraging direct and indirect relationships embedded in biomedical KGs, ECLIPSE provides context-aware CPI inference that is scalable to real-world settings. Code, datasets, and trained models are released to support reproducibility and reuse.

  • Open Access

    CBM KG: A Comorbidity-Centric Knowledge Graph Uncovering Causal Pathomechanisms Between COVID-19 and Neurodegenerative Diseases

    by Heval Atas Guvenilir, Priya Sethumadhavan, Abish Kaladharan, Renata Vieira de Sa, Adithya Sridhar, Undine Haferkamp, Ole Pless, Andrea Martí-Sarrias, Sandra Acosta, Tamas Letoha, et al.

    Summary: COVID-19 is increasingly recognized as a potential trigger or accelerator of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. To systematically explore the putative molecular and clinical associations between them, we present CBM KG (Causal Biological Mechanisms Knowledge Graph)—a manually curated, comorbidity-centric resource developed within the EU-funded COMMUTE project. CBM KG integrates over 2,800 cause-and-effect or correlative relationships from 63 peer-reviewed publications, highlighting key mechanisms such as viral entry routes, blood-brain barrier alteration, microglial activation, neuroinflammation, and APOE ε4-associated susceptibility. Each relationship in the graph is fully traceable to its source evidence, ensuring transparency and reproducibility. Unlike general-purpose or single disease-focused knowledge graphs, CBM KG is specifically designed to represent causal biological mechanisms spanning both infectious and neurodegenerative processes. By encoding directional, cause-and-effect relationships, it supports the interpretation of clinical co-occurrences through plausible mechanistic links between overlapping disease pathways, offering high-resolution insights at both molecular and clinical levels. Availability and implementation: The BEL files, Neo4j database, and Cytoscape visualization files are publicly available at: https://github.com/SCAI-BIO/CBM-Comorbidity-KG .

  • Top Cited Papers

    Learning functional properties of proteins with language models

    by Serbulent Unsal, Heval Atas, Muammer Albayrak, Kemal Turhan, Aybar C. Acar, Tunca Doğan


  • Open Access

    Protein domain-based prediction of drug/compound–target interactions and experimental validation on LIM kinases

    by Tunca Doğan, Ece Akhan Güzelcan, Marcus Baumann, Altay Koyas, Heval Atas, Ian R. Baxendale, Maria Martin, Rengul Cetin-Atalay

    Predictive approaches such as virtual screening have been used in drug discovery with the objective of reducing developmental time and costs. Current machine learning and network-based approaches have issues related to generalization, usability, or model interpretability, especially due to the complexity of target proteins’ structure/function, and bias in system training datasets. Here, we propose a new method “DRUIDom” (DRUg Interacting Domain prediction) to identify bio-interactions between drug candidate compounds and targets by utilizing the domain modularity of proteins, to overcome problems associated with current approaches. DRUIDom is composed of two methodological steps. First, ligands/compounds are statistically mapped to structural domains of their target proteins, with the aim of identifying their interactions. As such, other proteins containing the same mapped domain or domain pair become new candidate targets for the corresponding compounds. Next, a million-scale dataset of small molecule compounds, including those mapped to domains in the previous step, are clustered based on their molecular similarities, and their domain associations are propagated to other compounds within the same clusters. Experimentally verified bioactivity data points, obtained from public databases, are meticulously filtered to construct datasets of active/interacting and inactive/non-interacting drug/compound–target pairs (~2.9M data points), and used as training data for calculating parameters of compound–domain mappings, which led to 27,032 high-confidence associations between 250 domains and 8,165 compounds, and a finalized output of ~5 million new compound–protein interactions. DRUIDom is experimentally validated by syntheses and bioactivity analyses of compounds predicted to target LIM-kinase proteins, which play critical roles in the regulation of cell motility, cell cycle progression, and differentiation through actin filament dynamics. We showed that LIMK-inhibitor-2 and its derivatives significantly block the cancer cell migration through inhibition of LIMK phosphorylation and the downstream protein cofilin. One of the derivative compounds (LIMKi-2d) was identified as a promising candidate due to its action on resistant Mahlavu liver cancer cells. The results demonstrated that DRUIDom can be exploited to identify drug candidate compounds for intended targets and to predict new target proteins based on the defined compound–domain relationships. Datasets, results, and the source code of DRUIDom are fully-available at:https://github.com/cansyl/DRUIDom.


  • Open Access

    Protein Domain-Based Prediction of Compound–Target Interactions and Experimental Validation on LIM Kinases

    by Tunca Doğan, Ece Akhan Güzelcan, Marcus Baumann, Altay Koyas, Heval Atas, Ian Baxendale, Maria Martin, Rengul Cetin-Atalay

    Predictive approaches such as virtual screening have been used in drug discovery with the objective of reducing developmental time and costs. Current machine learning and network- based approaches have issues related to generalization, usability, or model interpretability, especially due to the complexity of target proteins’ structure/function, and bias in system training datasets. Here, we propose a new computational method “DRUIDom” to predict bio- interactions between drug candidate compounds and target proteins by utilizing the domain modularity of proteins, to overcome problems associated with current approaches. DRUIDom is composed of two methodological steps. First, ligands/compounds are statistically mapped to structural domains of their target proteins, with the aim of identifying physical or functional interactions. As such, other proteins containing the mapped domain or domain pair become new candidate targets for the corresponding compounds. Next, a million-scale dataset of small molecule compounds, including the ones mapped to domains in the previous step, are clustered based on their molecular similarities, and their domain associations are propagated to other compounds within the same clusters. Experimentally verified bioactivity data points, obtained from public databases, are meticulously filtered to construct datasets of active/interacting and inactive/non-interacting compound–target pairs (∼2.9M data points), and used as training data for calculating parameters of compound– domain mappings, which led to 27,032 high-confidence associations between 250 domains and 8,165 compounds, and a finalized output of ∼5 million new compound–protein interactions. DRUIDom is experimentally validated by syntheses and bioactivity analyses of compounds predicted to target LIM-kinase proteins, which play critical roles in the regulation of cell motility, cell cycle progression, and differentiation through actin filament dynamics. We showed that LIMK-inhibitor-2 and its derivatives significantly block the cancer cell migration through inhibition of LIMK phosphorylation and the downstream protein cofilin. One of the derivative compounds (LIMKi-2d) was identified as a promising candidate due to its action on resistant Mahlavu liver cancer cells. The results demonstrated that DRUIDom can be exploited to identify drug candidate compounds for intended targets and to predict new target proteins based on the defined compound–domain relationships. The datasets, results, and the source code of DRUIDom are fully-available at: https://github.com/cansyl/DRUIDom. Author Summary Drug development comprises several interlinked steps from designing drug candidate molecules to running clinical trials, with the aim to bring a new drug to market. A critical yet costly and labor-intensive stage is drug discovery, in which drug candidate molecules that specifically interact with the intended biomolecular target (mostly proteins) are identified. Lately, data-centric computational methods have been proposed to aid experimental procedures in drug discovery. These methods have the ability to rapidly assess large molecule libraries and reduce the time and cost of the process; however, most of them suffer from problems related to producing reliable biologically relevant results, preventing them from gaining real-world usage. Here, we have developed a new method called DRUIDom to predict unknown interactions between drugs/drug candidate compounds and biological targets by utilizing the modular structure of proteins. For this, we identify the domains, i.e., the evolutionary and functional building blocks of proteins, where these potential drug compounds can bind, and utilize this information along with protein domain annotations to predict new drug targets. We have tested the biological relevance of DRUIDom on selected proteins that play critical roles in the progression of numerous types of cancer. Cell-based experimental results indicated that predicted inhibitors are effective even on drug-resistant cancer cells. Our results suggest that DRUIDom produces novel and biologically relevant results that can be directly used in the early steps of the drug discovery process.